Navigation Links
Pharmasset to Present at Two Upcoming Investor Conferences
Date:3/3/2009

Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing four product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. An IND for PSI-7851, a second generation nucleotide HCV inhibitor was filed in January 2009. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation,, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk th
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
4. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Pharmasset to Webcast an Investor Event from the AASLD Meeting
7. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Roanoke, VA (PRWEB) July 22, 2014 ... as a young child. While most kids outgrow ... Tonelson did not. He is among the three million ... can range from mild to severe. Throughout his youth, ... attending in-school speech sessions and visits with private speech-and-language ...
(Date:7/22/2014)... 2014 BESLER Consulting, a leading ... for hospitals, is pleased to offer a complimentary ... to assist hospitals with analyzing their 2015 QualityNet ... on July 21 allow hospitals to validate their ... However, the data contained in these reports can ...
(Date:7/22/2014)... 2014 Kirby Lester, LLC, the leading ... includes streamlined functionality to perform a trackable double-count for ... Since a double-count of controlled medications is required, the ... quickly perform a second count of any tablet or ... of the second count up to 10 years. This ...
(Date:7/22/2014)... Hill, South Carolina (PRWEB) July 22, 2014 ... weight loss solution managed to lose 20 pounds. Unfortunately, the ... shaky and nauseated for the duration of her time using ... ‘manic’. One woman experienced heart flutters and insomnia as a ... woman experienced a heart attack at the age of 37 ...
(Date:7/22/2014)... 22, 2014 Ronald S. Weaver, ... Inglewood, Calif., today announced a heart transplant patient with ... Counterpulsation (EECP) therapy at Global Cardio Care Centers and ... , The patient, a 55-year-old Hispanic male, also ... Life Program, a nutrition and exercise lifestyle program in ...
Breaking Medicine News(10 mins):Health News:New Steps in the “Ballet of Speech” Create Life-Changing Possibilities for People Who Stutter 2Health News:New Steps in the “Ballet of Speech” Create Life-Changing Possibilities for People Who Stutter 3Health News:New Steps in the “Ballet of Speech” Create Life-Changing Possibilities for People Who Stutter 4Health News:Complimentary Re-admissions Analytics Tool Available From BESLER Consulting 2Health News:Kirby Lester KL1Plus Pharmacy Automation Perfect for Double-Counting & Tracking Prescriptions from Any Pharmacy Robot 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2Health News:Ronald S. Weaver, MD, Owner of Global Cardio Care Centers, Announces EECP Treatment Success for Cardiomyopathy Patient Who Needed Heart Transplant 2Health News:Ronald S. Weaver, MD, Owner of Global Cardio Care Centers, Announces EECP Treatment Success for Cardiomyopathy Patient Who Needed Heart Transplant 3
... ... professionals are turning to BurrellesLuce for valuable advice on making optimal use of Twitter and ... ... public relations practice, many PR professionals are turning to BurrellesLuce for valuable advice ...
... LINO LAKES, Minn., Aug. 26 Despite ... construction firms have been recognized by Minnesota Laborers-Employers Cooperation and ... 2008. , , Begun in 2007, the ... performance and proactive approach of Skilled Construction Union Laborers and ...
... , , WASHINGTON, Aug. ... who was a champion for vulnerable people throughout his life and a ... the midst of America,s great discussion of health care reform, Kennedy was ... We hope that Congress will honor his memory with the completion of ...
... arsenic from the body, according to a new study that ... the potentially toxic substance. The study found that some people ... the diet. Others store arsenic in their bodies, where it ... application of new methods for studying arsenic, is scheduled for ...
... , , WILMINGTON, ... comparative effectiveness study performed by HealthCore, Inc. in its August ... better clinical outcomes with oral controllers than inhaled corticosteroids. , ... requested the comparative effectiveness study to help ensure that its ...
... , JERICHO, N.Y., Aug. 26 Optimum ... New York metropolitan area businesses, today announced that Medical ... in Long Island, has selected Optimum Lightpath as its ... Optimum Lightpath,s 100% fiber Ethernet connection, Medical Arts Radiology ...
Cached Medicine News:Health News:PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce 2Health News:PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce 3Health News:Twenty-Two Regional Construction Firms Recognized for Their Commitment to Worker Safety 2Health News:Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products 2Health News:Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products 3Health News:Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products 4Health News:Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime, Anywhere Access to Patient Data and Communications 2Health News:Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime, Anywhere Access to Patient Data and Communications 3
(Date:7/22/2014)... 22, 2014 The steady decline of ... to previously rep-friendly specialties, according to the spring ... consulting firm ZS Associates.      AccessMonitor™ ... pharmaceutical sales teams. The report examines how often ... the pharmaceutical sales reps who visit their offices. ...
(Date:7/22/2014)... 2014  UL (Underwriters Laboratories), a global safety ... and Drug Administration (FDA) has recognized two UL ... devices incorporating lithium or nickel-based batteries. The two ... and Commercial Batteries, and UL 1642 - Standard ... standards are standards recognized by the FDA for ...
(Date:7/22/2014)... Texas , July 22, 2014 Quantum Materials Corporation ... and Mr. John Heaton to the Board of Directors. ... Dr. Ghassan Jabbour , QMC Chief Science Officer and Board ... Michael Wong of Rice University and Mr. Tomio Gotoh ... . " Quantum Materials welcomes two ...
Breaking Medicine Technology:Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... , Feb. 18 R-Squared, an industry ... alliance with IMS Health Inc., to help pharmaceutical and ... state transparency and marketing disclosure laws, known as "aggregate ... state-of-the-art SpendTracker® compliance application platform will be deployed to ...
... , , FRANKLIN, Mass. , ... Bulletin Board: ECTE), a company developing the needle-free Symphony™ ... monitoring (tCGM) system and the Prelude™ SkinPrep System for ... made a significant advance in the product design of ...
Cached Medicine Technology:R-Squared Forms Strategic Relationship with IMS Health 2Echo Therapeutics Announces Significant Product Development Milestone: The Completion of Next Generation Electronic Components for Its Revolutionary, Patented Symphony(TM) tCGM System 2Echo Therapeutics Announces Significant Product Development Milestone: The Completion of Next Generation Electronic Components for Its Revolutionary, Patented Symphony(TM) tCGM System 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: